On November 4, 2025 AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") reported that data from the completed Phase 2 cisplatin-resistant advanced recurrent ovarian cancer clinical study utilizing Ampligen (rintatolimod) was accepted in a late-breaking abstract at the 40th Annual SITC (Free SITC Whitepaper) Meeting being held November 5-9, 2025 at National Harbor, MD.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the poster presentation are as follows:
Title: A Phase II Trial of Combination Locoregional Chemoimmunotherapy in Recurrent Platinum-Sensitive Ovarian Cancer Triggers a T Lymphotactic Response Correlating with Clinical Outcomes
Presenting Author: Mackenzy M. Radolec, MD, Clinical Assistant Professor, Department of Obstetrics, Gynecology and Reproductive Sciences, UPMC Magee-Women’s Hospital
Abstract Number: 1343
Date: Friday, November 7, 2025
Location: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center
For more information about the SITC (Free SITC Whitepaper) Annual Meeting, please visit sitcancer.org.
(Press release, AIM ImmunoTech, NOV 4, 2025, View Source [SID1234659340])